August 09, 2016 09:00 AM Eastern Daylight Time
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, today announced the final closing of its Series C financing bringing an additional $10 million into the company and completing the Series C at $48.5 million. Proceeds from the financing will be used to advance development of Iconic’s lead molecule ICON-1 in retinal diseases as well begin clinical trials in ocular melanoma, Iconic’s first oncology indication. The final closing included new investor Xeraya Capital. Xeraya joins existing investors MPM Capital, HBM Healthcare Investments, H.I.G. BioHealth Partners, Lundbeckfonden Ventures, Cormorant Asset Management, and Osage University Partners in the Series C capital raise.
Investment Supports Further Product/Technology Improvements and Expanded Access to the Company's Global, Pivotal Study
Clinicians Are Now Enrolling Patients at Sites in France, Spain and Turkey in Addition to US, UK and Germany
GAITHERSBURG, Md., July 25, 2016 /PRNewswire/ -- Vtesse, Inc., a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, announced today that it has secured $17 million in additional Series A funding in support of its global, pivotal clinical trial of VTS-270 for Niemann-Pick Type C1 disease ("NPC").
Clinically and statistically significant reduction in signs and symptoms of moderate to severe atopic dermatitis
- 50% (p=0.01) improvement on the eczema severity score (EASI) at week 8
- ZPL-389 was well tolerated with a safety profile comparable to placebo
- Phase 2b study to commence in H2 2016
- Full study data presented at European Academy of Allergy and Clinical Immunology 35th Annual Congress 2016 Vienna, Austria on 12 June
50% (p=0.01) improvement on EASI score at week 8
- Full data to be presented at the EAACI Congress, 12 June 2016, Vienna, Austria in a Late Breaking Oral Session
Discovery Park, Sandwich, UK, 16 May, 2016 - Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs for the treatment of inflammatory skin disorders, is today pleased to announce positive top line results from its first Phase 2a proof of concept study of ZPL-389 for the treatment of moderate to severe atopic dermatitis.
EDINBURGH, UK (PRWEB) MAY 12, 2016
DySIS Medical Ltd. (DySIS), an innovative women’s health company that offers a new cervical imaging technology (dynamic spectral imaging) for women with abnormal Pap smears, announced today it will present initial findings from the IMproved PRactice Outcomes and Value Excellence in Colposcopy (IMPROVE-COLPO) at the Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG), to be held in Washington, D.C., May 14-17.
|Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste|